secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0000950170-24-003420
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix names new CEO and CFO; Q4 net sales $200.3M, pro forma up 7.5%
-----------------------------------------------------------------------

- Massimo Calafiore appointed CEO, effective Jan 8, 2024; received $7.5M in inducement equity awards (RSUs + options).
- Julie Andrews named CFO, effective Jan 15; base salary $475K, target bonus 70%, sign-on equity $1.8M.
- Kevin Kenny departed as officer Jan 8; eligible for severance and $500/hr consulting for 12 months.
- Q4 preliminary net sales $200.3M, +63.8% reported (+7.5% pro forma); BGT up 15.3%.
- Full-year 2023 net sales $746.5M, +62% reported (+6.5% pro forma).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/0000950170-24-003420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017024003420/ofix-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer